NCT02016729View on ClinicalTrials.gov

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

April 19, 2017

Study Completion Date

July 31, 2017

Conditions
Advanced MalignancyCancerOncologyOncology PatientsAcute Myeloid Leukemia
Interventions
DRUG

AMG 232

Given an an oral tablet in escalating doses.

DRUG

Trametinib

Trametinib is an oral tablet given in a fixed dose.

Trial Locations (5)

14263

Research Site, Buffalo

28204

Research Site, Charlotte

35294

Research Site, Birmingham

84112

Research Site, Salt Lake City

98101

Research Site, Seattle

Sponsors
All Listed Sponsors
lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT02016729 - A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter